Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals' stock experienced a significant increase of 480.17% between January 2025 and January 2026, driven by positive Phase 3 results for Roche's giredestrant. In November 2025, Olema raised approximately US$218.5 million through a public offering. Insider selling occurred in Q4 2025. Several firms issued or reiterated "Buy" or "Overweight" ratings, with price targets ranging from $32.00 to $60.00. Olema was included on Citigroup's 90-day catalyst watchlist. The company reported its third-quarter 2025 financial and operating results on November 10, 2025. The stock price decreased by -5.12% on January 13, 2026, and was down 8.6% on January 8, 2026, after missing Q3 2025 EPS estimates.

As a clinical-stage biopharmaceutical company, Olema Pharmaceuticals does not have traditional product demand seasonality. However, the global estrogen receptor-positive breast cancer treatment market is experiencing robust growth and is projected to reach USD 33.7 billion by 2030. A seasonal chart analysis of OLMA stock indicates a period of seasonal strength for the Healthcare sector from April 25 to December 4, with a historical "Buy Date" of May 23 and "Sell Date" of September 15.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for women's cancers, particularly breast cancer. Their lead product candidate, Palazestrant (OP-1250), is in Phase 3 clinical trials as a monotherapy for recurrent, locally advanced, or metastatic ER+/HER2- breast cancer and is also being evaluated in combination studies. Additionally, Olema is developing OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6, which is in Phase 1 clinical trial for ER+/HER2- metastatic breast cancer and other cancers.

Olema Pharmaceuticals, Inc. is headquartered in San Francisco, California, and has operations in Cambridge, Massachusetts. While primarily focused on the U.S. market, Olema has a global perspective, collaborating with Novartis for the Phase 3 OPERA-02 trial and planning to expand into Europe and Asia by 2024.

Olema Pharmaceuticals has maintained a generally positive brand reputation, with a news sentiment score of 0.40. Media mentions have increased, and analyst sentiment is positive, with a consensus rating of "Moderate Buy" and an average price target of $41.00. The stock price surge was fueled by a "rising tide" effect in the breast cancer treatment market. The company's presentation at the 44th Annual J.P. Morgan Healthcare Conference enhanced its visibility. Olema has a strong liquidity position but has reported negative earnings and cash flow from operations.

Olema Pharmaceuticals, Inc. has a significant institutional presence, with 266 institutional owners holding 91.78% of the stock, and insiders owning 16.36%. Bain Capital Life Sciences Investors LLC is the largest individual shareholder, holding 10.92% of the company. Insider selling by key executives occurred in Q4 2025.